A. Creighton

发表

Degradation of ATM-Independent Decatenation Checkpoint Function in Human Cells is Secondary to Inactivation of p53 and Correlated with Chromosomal Destabilization

W. Kaufmann, D. Simpson, D. Galloway, 2002, Cell cycle.

A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells

D. J. Clarke, C. Downes, Robert T. Johnson, 1994, Nature.

A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells

D. J. Clarke, C. Downes, Robert T. Johnson, 1994, Nature.

Conjugation of monoclonal antibodies to a synthetic peptide substrate for protein kinase: a method for labelling antibodies with 32P.

P. Parker, B. Foxwell, W. Jeffery, 1988, British Journal of Cancer.

Metal binding by pharmaceuticals. part 2. interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumour agent ICRF 159 and its inactive homologue ICRF 192

David R. Williams, A. Creighton, P. M. May, 1982, Agents and Actions.

The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat

T. K. Yeung, J. Hopewell, R. Jaenke, 2004, Cancer Chemotherapy and Pharmacology.

Recombinant anti-human melanoma antibodies are versatile molecules.

M. Mariani, P. Natali, D. Neri, 1996, The Journal of investigative dermatology.

Metal binding by pharmaceuticals. Part 5. Interaction of Cd(II), Ni(II) and Pb(II) with the intracellular hydrolysis products of the anti-tumour agent ICRF 159 and its inactive homologue ICRF 192

David R. Williams, A. Creighton, P. M. May, 1984, Agents and Actions.

ICRF 159-induced cell-cycle perturbation in vitro: its relationship to inhibition of colony-forming ability.

A. Creighton, D. Edgar, 1981, British Journal of Cancer.

Comparison of the protective effect of ICRF-187 and structurally related analogues against acute daunorubicin toxicity in Syrian golden hamsters.

V. Ferrans, D. Witiak, E. Herman, 1985, Research communications in chemical pathology and pharmacology.

Radioactive labeling of recombinant antibody fragments by phosphorylation using human casein kinase II and [γ-32P]-ATP

G. Winter, R. Marais, Y. Light, 1996, Nature Biotechnology.

Chelating agents as antitumour drugs: Formation of chelating agents from the antitumour pro-drug, razoxane

A. Creighton, T. Murphy, K. Nolan, 1990 .